Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | RAB9A | P51151 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 2/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | MGAM | O43451 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | SI | P14410 | 1/20 | 0.40 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22491241 | 0.97 | MAPT (0.51) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7424619 | 0.76 | MRE11 (0.46) | MAPTRAB9ANPC1APPCASP3 | |
| SCHEMBL5869382 | 0.76 | MEN1 (0.60) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5869395 | 0.76 | MEN1 (0.60) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5869368 | 0.76 | MEN1 (0.60) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5869718 | 0.75 | ALDH1A1 (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5869710 | 0.75 | ALDH1A1 (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5869724 | 0.75 | ALDH1A1 (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6931298 | 0.75 | ALDH1A1 (0.53) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL7424611 | 0.72 | ELOVL1 (0.46) | MAPTRAB9ANPC1APPCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2022-05-24 | — | — | US | disclosed |
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN IN DER HELMHOLTZ-GEMEINSCHAFT (DE) | 2020-11-19 | — | — | US | disclosed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360258-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | ACE, ACE2, TYR | MAPT 1460/4885RAB9A 2722/4885NPC1 3301/4885 |
| US-11337909-B2 | Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation | ACE, ACE2, TYR | MAPT 1460/4885RAB9A 2722/4885NPC1 3301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.